Abstract
Vaccines are today considered one of the most effective means against the Sars-CoV-2 pandemic. The BNT162b2 vaccine by Pfizer/BioNTech has been massively administered throughout the globe; since its approval, a wide spectrum of cutaneous reactions has been reported. Here we report the case of a 52-year-old Caucasian male who presented with an acute febrile eruption that arose 72 h after the first dose of the BNT162b2 vaccine. The clinicopathological findings were consistent with Sweet’s syndrome. The short latency time suggested a possible role of the vaccine in triggering Sweet’s syndrome in this case.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference25 articles.
1. Coronavirus (COVID-19) Dashboardhttps://covid19.who.int/
2. Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19 [Media Release]https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world
3. The European Commission Authorized the First Vaccine to Prevent COVID-19 in the EU, Following Evaluation by EMAhttps://ec.europa.eu/health/documents/community-register/html/h1528.htm
4. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following
COVID
‐19 vaccination
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献